Serum Deprivation of Mesenchymal Stem Cells Improves Exosome Activity and Alters Lipid and Protein Composition
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Haraszti, Reka A.Miller, Rachael
Dubuke, Michelle L.
Coles, Andrew H.
Didiot, Marie C.
Echeverria, Dimas
Stoppato, Matteo
Sere, Yves Y.
Leszyk, John D.
Alterman, Julia F.
Godinho, Bruno M. D. C.
Hassler, Matthew R.
Wollacott, Rachel
Wang, Yan
Shaffer, Scott A.
Aronin, Neil
Khvorova, Anastasia
UMass Chan Affiliations
Graduate School of Biomedical Sciences, Interdisciplinary Graduate ProgramProgram in Molecular Medicine
MassBiologics
Department of Biochemistry and Molecular Pharmacology
Mass Spectrometry Facility
Department of Medicine
RNA Therapeutics Institute
Document Type
Journal ArticlePublication Date
2019-05-27Keywords
BiochemistryBiological Sciences
Lipidomics
Molecular Biology
Proteomics
UMCCTS funding
Amino Acids, Peptides, and Proteins
Biochemistry
Cell Biology
Cells
Enzymes and Coenzymes
Lipids
Molecular Biology
Nucleic Acids, Nucleotides, and Nucleosides
Therapeutics
Metadata
Show full item recordAbstract
Exosomes can serve as delivery vehicles for advanced therapeutics. The components necessary and sufficient to support exosomal delivery have not been established. Here we connect biochemical composition and activity of exosomes to optimize exosome-mediated delivery of small interfering RNAs (siRNAs). This information is used to create effective artificial exosomes. We show that serum-deprived mesenchymal stem cells produce exosomes up to 22-fold more effective at delivering siRNAs to neurons than exosomes derived from control cells. Proteinase treatment of exosomes stops siRNA transfer, indicating that surface proteins on exosomes are involved in trafficking. Proteomic and lipidomic analyses show that exosomes derived in serum-deprived conditions are enriched in six protein pathways and one lipid class, dilysocardiolipin. Inspired by these findings, we engineer an "artificial exosome," in which the incorporation of one lipid (dilysocardiolipin) and three proteins (Rab7, Desmoplakin, and AHSG) into conventional neutral liposomes produces vesicles that mimic cargo delivering activity of natural exosomes.Source
iScience. 2019 May 27;16:230-241. doi: 10.1016/j.isci.2019.05.029. [Epub ahead of print] Link to article on publisher's site
DOI
10.1016/j.isci.2019.05.029Permanent Link to this Item
http://hdl.handle.net/20.500.14038/41056PubMed ID
31195240Notes
Full author list omitted for brevity. For the full list of authors, see article.
Related Resources
Rights
Copyright 2019 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Distribution License
http://creativecommons.org/licenses/by-nc-nd/4.0/ae974a485f413a2113503eed53cd6c53
10.1016/j.isci.2019.05.029
Scopus Count
Except where otherwise noted, this item's license is described as Copyright 2019 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).